Claims

1. A composition comprising menotropin for use in the treatment of infertility in a patient to thereby promote the development of euploid blastocysts for future blastocyst transfer to the patient, the treatment comprising:

identifying a patient having a serum antimullerian hormone (AMH) level ≥ 5.2 6 0.5 ng/ml and an antral follicle count (AFC) ≥ 10 in both ovaries combined prior to treatment/stimulation; and administering a dose of, or a dose equivalent to, 75 to 300 IU hMG per day from day 1 to at least day 5 of treatment.

2. A composition for use according to claim 1 wherein the treatment to promote the development of euploid blastocysts for future blastocyst transfer increases the proportion/percentage of euploid blastocysts compared to the proportion/percentage of aneuploid blastocysts and/or reduces aneuploidy rate.

3. A composition for use according to any preceding claim wherein the treatment further comprises:

administering hCG to trigger ovulation.

4. A composition for use according to any preceding claim wherein the menotropin is highly purified menotropin (HPhMG).

5. A composition for use according to any preceding claim wherein the treatment comprises a step of administration to the patient a dose of, or a dose equivalent to, 75 to 200 IU HP-hMG per day from day 1 to at least day 5 of treatment.

6. A composition for use according to any preceding claim wherein the treatment comprises a step of administration to the patient a dose of, or dose equivalent to, 150 IU HP-hMG per day from day 1 to at least day 5 of treatment.

7. A composition for use according to any preceding claim, comprising a further step of administering a GnRH antagonist on day 6 of treatment.